Fluid Biomarker Core

FBM核心摘要/摘要 阿尔茨海默病(AD)超灵敏血液生物标志物检测的研究进展 提示血浆生物标志物可以为AD的研究和临床实践带来革命性的变化。流体生物标志物和 方法(FBM)核心是在PPG4中创建的，以响应这些进展，并将负责 协调血液采集、分析前程序、储存、分析和持续血液供应 生物标志物对项目的价值。FBM核心将为所有项目生成结果，并将与 所有其他核心。我们将以易于使用的格式提供血液生物标志物的质量控制结果 按项目对与其目标相关的分析进行分析。与神经成像和 神经病理团队，我们将为先前由 FBM核心团队成员和其他小组反对得到更好验证的神经成像和尸检结果。 FBM核心将寻求与AD和相关领域的几个大型多站点研究合作 痴呆症：使用大数据方法推进血液生物标志物的知识。我们将每月举办一次 与其他PPG研究人员会面，讨论血液收集和分析，以及讨论 血液生物标记物的方法学和科学方面。FBM Core还将为学生提供培训， 博士后，以及流体生物标记物方法和分析方面的教师。需要强调的是，优化 在之前的PPG周期中，神经成像生物标记物技术的发展使FBM Core处于特权地位 使用这些最先进的神经成像结果来支持使用新血液所获得的措施 生物标记物分析。FBM核心的具体目标是：(目标1)协调收集、分析前 跨PPG4的血浆生物标记物的程序、存储和分析。(目标2)提供优质- Aβ、tau、神经退行性变和神经炎症的受控血浆生物标志物值支持AIMS 在项目1-4中有详细说明。(目标3)与成像生物标记物方法学核心合作，我们 目的验证血浆生物标记物检测与神经影像结果的相关性。(AIM 4)与 神经病理小组(项目4)，我们的目标是验证血浆生物标记物分析与尸检病理对照 结果。(目标5)对学生、博士后研究员和教职员工进行血浆生物标记物方法培训。在 目前的研究，我们将生成第一个大规模的纵向数据集，包括血液和神经成像测量 星形胶质细胞增多症，Aβ，tau和神经变性。由项目生成的结果与由 FBM核心将有助于阐明AD多种病理之间的复杂相互作用。验证 血液生物标志物测量与更好地建立的神经成像和尸检结果的对比将 指出使用这些血浆生物标志物来识别AD的脑病理的优势和注意事项。

FBM Core Summary/Abstract Recent advances in ultrasensitive blood biomarker assays for Alzheimer’s disease (AD) pathophysiology suggest that plasma biomarkers can revolutionize AD research and clinical practice. The Fluid Biomarker and Methodology (FBM) Core was created in PPG4 in response to these advances and will be responsible for coordinating blood collections, pre-analytical procedures, banking, analysis, and supplying continuous blood biomarker values to the projects. The FBM Core will generate results for all projects and will be integrated with all other cores. We will provide quality-controlled results of blood biomarkers in a format that can be easily used by projects for the analyzes associated with their aims. In collaboration with the neuroimaging and neuropathology teams, we will contribute to the validation of plasma biomarker assays previously developed by FBM Core team members and other groups against better-validated neuroimaging and postmortem outcomes. The FBM Core will seek to collaborate with several large-scale multi-site studies in the field of AD and related dementia to advance the knowledge of blood biomarkers using a big data approach. We will hold monthly meetings with other PPG researchers to discuss blood collection and analysis, as well as to discuss methodological and scientific aspects of blood biomarkers. The FBM Core will also provide training for students, postdocs, and faculty in fluid biomarker methods and analyses. It is important to emphasize that the optimization of neuroimaging biomarker techniques in the previous PPG cycles has placed the FBM Core in a privileged position to use these state-of-art neuroimaging outcomes to support the measures obtained with the new blood biomarker assays. The specific aims of the FBM Core are: (Aim 1) To coordinate the collection, pre-analytical procedures, storage, and analysis of blood plasma biomarkers across the PPG4. (Aim 2) To provide quality- controlled plasma biomarker values of Aβ, tau, neurodegeneration, and neuroinflammation in support of the aims described in detail in Projects 1-4. (Aim 3) In collaboration with the Imaging Biomarkers Methodology Core, we aim to validate plasma biomarker assays against neuroimaging outcomes. (Aim 4) In collaboration with the neuropathology team (Project 4), we aim to validate plasma biomarker assays against postmortem pathological outcomes. (Aim 5) To train students, post-doctoral fellows, and faculty in plasma biomarker methods. In the present study, we will generate the first large-scale longitudinal dataset with blood and neuroimaging measures of astrogliosis, Aβ, tau, and neurodegeneration. The results generated by the projects with the data provided by the FBM Core will help to elucidate the complex interactions between multiple pathologies in AD. The validation of blood biomarker measurements against better-established neuroimaging and postmortem outcomes will indicate the advantages and caveats of using these plasma biomarkers to identify brain pathologies in AD.